SCHEMBL3560867

SCHEMBL3560867

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nc(NS(C)(=O)=O)no4)ccc3n(C)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 12/20 0.42
▸ GABRA1 P14867 2/20 0.42
▸ ADRA2C P18825 2/20 0.42
▸ SLC6A3 Q01959 2/20 0.42
▸ ADRB3 P13945 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ RIPK2 O43353 1/20 0.37
▸ NOD2 Q9HC29 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MAPT P10636 1/20 0.35
▸ CNR2 P34972 11/20 0.35
▸ PTGER3 P43115 1/20 0.34
▸ EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380418 0.86 KDM4E (0.41) CNR1GABRA1ADRA2CSLC6A3ADRB3
SCHEMBL3577543 0.85 KDM4E (0.41) CNR1GABRA1ADRA2CSLC6A3KDM4E
SCHEMBL3571986 0.83 CNR1 (0.37) CNR1GABRA1ADRA2CSLC6A3KDM4E
SCHEMBL3567229 0.82 CNR1 (0.40) CNR1GABRA1ADRA2CSLC6A3ADRB3
SCHEMBL3629309 0.79 CNR1 (0.40) CNR1GABRA1ADRA2CSLC6A3ADRB3
SCHEMBL1339468 0.78 KDM4E (0.41) CNR1GABRA1ADRA2CSLC6A3ADRB3
SCHEMBL1339427 0.78 CNR1 (0.38) CNR1GABRA1ADRA2CSLC6A3KDM4E
SCHEMBL1338174 0.77 CSF1R (0.38) CNR1KDM4EALDH1A1GAAHPGD
SCHEMBL1338764 0.77 BRD4 (0.41) CNR1GABRA1ADRA2CSLC6A3KDM4E
SCHEMBL3574329 0.77 HSD17B10 (0.42) CNR1KDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD CNR1 387/4885GABRA1 2242/4885ADRA2C 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback